Table 3. Lifetime ratesa of colorectal cancer incidence and mortality per 100 000 population, percentage of cases which would be detected by screening, surveillance and symptomatically, and percentage reductions in incidence and mortality compared with no screening, for core screening scenarios.
Incidence
|
|||||||||
---|---|---|---|---|---|---|---|---|---|
Screen detected CRC
|
Surveillance-detected CRCb
|
Symptomatic CRC
|
Mortality
|
||||||
Scenario | Rate | % of cases | Rate | % of cases | Rate | % of cases | % reduction in CRC incidencec | CRC mortality rate | % reduction in CRC mortalityc |
No screening | 0 | — | 0 | — | 5158 | 100 | — | 2287 | — |
gFOBT at 55–74 years | 695 | 13.6 | 11 | 0.2 | 4401 | 86.2 | 1.0 | 2016 | 11.8 |
FIT at 55–74 years | 1313 | 29.8 | 78 | 1.8 | 3010 | 68.4 | 14.7 | 1465 | 36.0 |
FSIG once at 60 years | 138 | 2.8 | 25 | 0.5 | 4742 | 96.7 | 4.9 | 2116 | 7.5 |
Abbreviations: CRC=colorectal cancer; FIT=faecal immunochemical test; FSIG=flexible sigmoidoscopy; gFOBT=guaiac-based faecal occult blood test.
Over the entire lifetime of the cohort, therefore, for gFOBT and FIT includes 10 screening rounds.
CRC detected at surveillance among those with intermediate/high-risk adenomas found at screening.
Each incremental value compares values for that strategy with common baseline of no screening.